Abstract
Background:
Ramsay Hunt Syndrome TypeII (RHSII), also known as herpes zoster oticus, is an example of reactivation of the varicella-zoster virus (VZV) at the geniculate ganglion. Although rare, reports of VZV vasculopathy secondary to RHSII have been documented. The aim of this review was to analyze clinical and neuroimaging findings, laboratory findings, treatment and outcome of these patients.
Methods:
We report a literature review that includes all case reports identified via PubMed on RHSII complicated by VZV Vasculopathy. All epidemiological, clinical, imaging, virologic, treatment and outcome data collected are described.
Results:
We analyzed a total of RHSII complicated by VZV vasculopathy 9 cases (median age 54.0 ± 16.5 years, range 24–75), and 22.2% (2/9) were immunocompromised. Apart from RHSII-related symptoms, the most common symptom is cranial nerve injury (77.8%, 7/9). Abnormal brain imaging in 88.9% (8/9), including 8 cases of ischemic stroke and one of which was accompanied by hemorrhagic stroke. Vascular studies revealing abnormalities in 66.7% (6/9) cases. Cerebrospinal fluid (CSF) analysis revealed 5 (55.6%, 5/9) cases were positive for VZV IgG, and 5 (55.6%, 5/9) cases tested positive for VZV DNA. All 9 patients received acyclovir treatment, with 77.8% (7/9) combination with corticosteroids. A favorable outcome was observed in 88.9% (8/9) of the patients. We analyzed a total of 9 cases of RHS II complicated by VZV vasculopathy. The median age was 54.0 ± 16.5 years (range 24–75), with 22.2% (2/9) being immunocompromised. In addition to RHS II-related symptoms, cranial nerve injury was the most common symptom, occurring in 77.8% (7/9) of cases. Abnormal brain imaging was observed in 88.9% (8/9) of patients, including 8 cases of ischemic stroke, one of which was accompanied by hemorrhagic stroke. Vascular studies revealed abnormalities in 66.7% (6/9) of cases. Cerebrospinal fluid (CSF) analysis showed that 5 patients (55.6%) were positive for VZV IgG, and 5 patients (55.6%) tested positive for VZV DNA. All 9 patients received acyclovir treatment, with 77.8% (7/9) also receiving corticosteroids. A favorable outcome was observed in 88.9% (8/9) of the patients.
Conclusion:
VZV vasculopathy, as a rare complication of RHSII, can occur in both immunocompetent and immunosuppressed patients. Ophthalmoplegia is its primary clinical manifestation. Detection of VZV IgG antibodies and VZV DNA in the CSF has equal sensitivity. Antiviral combined with steroid therapy represents the optimal treatment approach.
Introduction
Varicella zoster virus (VZV) is a double-stranded DNA neurotrophic alpha-herpesvirus that replicates almost exclusively in human cells and tissues (1). Primary infection occurs mostly during childhood and presents as varicella (chickenpox). Afterward, the virus may retrogradely travel to the sensory neuron cell bodies within the ganglion, where it establishes a latent infection. Any immune instability or deficiency (such as chemotherapy, tumors, stress, etc.) can trigger the virus to reactivate and replicate. Subsequently, it travels via anterograde axonal transport to the dermatome associated with the affected ganglion, resulting in the development of herpes zoster (2). Ramsay Hunt Syndrome TypeII (RHSII), is an example of reactivation of the VZV at the geniculate ganglion, characterized by ipsilateral facial paralysis, otic pain, erythematous vesicular rash on the ear or in the mouth. Unlike Bell’s palsy, RHSII has a worse prognosis and often results in facial paralysis and postherpetic neuralgia (3). In some cases, VZV can also spread to the arteries of the central nervous system, eventually leading to a uncommon but well-known complication called VZV vasculopathy (4). This was first recognized based on the occurrence of contralateral hemiplegia after trigeminal distribution zoster caused disease to the cerebral arteries (5). Given the significant increase in stroke risk during the first year following herpes zoster infection, researchers have come to realize that VZV vasculopathy may be more common than previously thought (6, 7). Therefore, although VZV vasculopathy is rarely observed in association with RHSII, it is a complication that must not be overlooked, particularly given the treatability of VZV vasculopathy (8). Here, we reviewed the literature and found a total of 9 cases of adult-onset RHSIIaccompanied by VZV vasculopathy, aiming to illustrate the clinical presentations, imaging features, virologic findings, treatment approaches, and outcomes (9–17). To our knowledge, no previous research has addressed this topic, and we believe that this review provides valuable insights for clinicians, aiding in the early recognition and treatment of these complex cases, thereby improving patient outcomes.
Materials and methods
We performed a comprehensive literature review up to 2024, encompassing all case reports retrieved from PubMed using the search terms “VZV vasculopathy,” “contralateral hemiplegia,” “stroke,” “ischemia,” “infarction,” “hemorrhage” and “varicella-zoster virus,” “herpes zoster oticus” or “Ramsay Hunt Syndrome.” Case reports cited in the collected articles were added to the list. Articles written in English were included. We included all epidemiological, clinical, imaging, Cerebrospinal fluid (CSF) test, treatment, and outcome. RHSIIand VZV vasculopathy were confirmed according to diagnostic criteria by consensus article (3, 8). We excluded patients who had incomplete medical histories and imaging data (Figure 1). Given that this was a review of published literature, there was no requirement for an ethics board approval. Based on brain imaging of the cases, arterial disease was classified as large artery, small artery or mixed. The Large arteries disease refers to involvement of the internal carotid artery, the anterior cerebral artery and the middle cerebral artery in the anterior circulation, and the posterior cerebral artery, the vertebral artery and basilar artery in the posterior circulation. In contrast, diseases of the penetrating arteries (e.g., the lenticulostriate arteries) supplying the deep-seated structures were considered small artery diseases (18). We used the Modified Rankin Scale (mRS) as the outcome assessment measure. The definition of poor outcome was mRS greater than or equal to 3 points, while good outcome defined as mRS score of 0–2 points.
Figure 1
Flow chart of patient selection.
Results
In the 9 articles reviewed, we identified 9 patients with a clinical diagnosis consistent with RHS II complicated with VZV vasculopathy. The epidemiological, and clinical, imaging, virologic, treatment and outcome, are summarized in Table 1. The average age of the 9 patients was 54.0 ± 16.5 years, ranging from 24 to 75 years, with a male-to-female ratio of 4:5. Two patients were immunosuppressed: one due to HIV infection, and the other due to oral corticosteroid therapy for CREST syndrome. Only one patient reported a history of prior herpes zoster infection. In the clinical presentation of RHSII, only 55.6% (5/9) presented with vesicular rash, while auditory changes were the most common accompanying symptom (44.4%,4/9), followed by dizziness, nystagmus (both 22.2%, 2/9). Other central nervous system clinical features include ophthalmoplegia (55.6%, 5/9), abnormal facial sensation (33.3%, 3/9), dysarthria/dysphagia (22.2%, 2/9), ataxia (33.3%, 3/9), hemiparesis (22.2%, 2/9) and signs of encephalitis (33.3%, 3/9).
Table 1
| Reference | Gender, age (years) | Comorbidity | History of chicken or vaccination against VZV | Clinical features | Time from symptom onset to MRI | MRI abnormalities | Affected vessel | CSF findings | IV or oral (days) | Outcome (mRS) |
|---|---|---|---|---|---|---|---|---|---|---|
| Chan et al. (11) | Female, 55 | Diabetes, Hypertension, Hyperlipidemia | No | Right ear vesicular rash, right peripheral facial palsy, diplopia, gait and limb ataxia, | 6 weeks | Ischemic lesions in left superior occipital | Left posterior cerebral artery | Elevation protein, cells 700 × 106/L (lymphocyte-predominant), VZV PCR (+) | IV acyclovir 21 days, oral prednisone 6 weeks | Facial palsy completely resolved, Significant improvement in cerebellar symptoms (1) |
| Calabria et al. (10) | Female, 67 | Diabetes, Hypertension | No | Left ear vesicular rash, left peripheral facial palsy, left facial pain, gait and limb ataxia | 14 days | Ischemic lesions in left pons, left midbrain, right periventricular area | Normal | Elevation protein, cells 40 × 106/L (lymphocyte predominant), VZV PCR (+), VZV IgG (+) | IV acyclovir 10 days | Mild facial weakness (1) |
| Labbad et al. (13) | Female, 41 | No | Chickenpox | Right peripheral facial palsy, right sided deafness, right oculomotor nerve palsy | 1 year | Ischemic lesions in right occipital and temporal lobes | Normal | Elevation protein, cells 20 × 106/L (lymphocyte-predominant), VZV IgG (+) | IV acyclovir14 days | Mild facial weakness and deafness, oculomotor nerve palsy (2) |
| Upreti and Rathod (17) | Female, 45 | No | No | Left ear vesicular rash, left sided deafness, left peripheral facial palsy, reduced facial sensation of left, voice change, mild dysphagia, absent eyeball abduction | 7 days | Normal | Left internal carotid artery | Biochemistry and cytology was normal, VZV IgG (+) | IV acyclovir 10 days oral prednisolone 20 days antiplatelet | Mild facial weakness, hearing loss persisted (1) |
| González-Otárula. (12) | Male, 54 | No | No | Left peripheral facial palsy, left sided deafness, horizontal nystagmus, dizzy | 3 days | Ischemic lesions in left vermis, left pons and medium cerebellar peduncle, right striatum nuclei | Anterior cerebral arteries posterior cerebral artery | Elevation protein, without pleocytosis, VZV PCR (+) | IV acyclovir 14 days methylprednisolone 5 days | Complete recovery (0) |
| Ortiz et al. (15) | Female, 24 | HIV | No | Left ear vesicular rash, left peripheral facial palsy, headache, mild dysarthria, mild dysphagia, left hemiparesis | 1 month | Ischemic lesions in right pontine | Vertebral and basilar artery left internal carotid artery left middle cerebral artery left anterior cerebral artery | Elevation protein, cells 9 × 106/L (lymphocyte-predominant), VZV PCR (+) | IV acyclovir 7 days (oral 8 weeks) IV methylprednisolone 7 days (oral 8 week) | Complete recovery (0) |
| Ohtomo et al. (14) | Male, 75 | Prostate cancer (chemotherapy) | No | Left ear vesicular rash, left peripheral facial palsy, fever, headache, nuchal stiffness | 2 weeks | Ischemic lesions in in right insula; microbleeding in the left anterior cingulate gyrus and the midbrain interpeduncular fossa. | Normal | Elevation protein, cells 640 × 106/L (neutrophils-predominant) VZV PCR (+), IgM (+) | IV acyclovir 14 days (oral 2 months) oral dexamethasone 2 months | Complete recovery (0) |
| Russman et al. (16) | Male, 51 | CREST syndrome (oral prednisone) | No | Right peripheral facial palsy, right sided deafness, dizzy, confusion, left hemiparesis, ataxia, nystagmus, left oculomotor nerve palsy, seizure | 1 month | Ischemic lesions in brainstem, thalamus, caudate nucleus, occipital, parietal, frontal lobes and left temporal lobe | Left middle cerebral artery right posterior cerebral artery | Biochemistry and cytology was normal, VZV IgG (+) | Ivacyclovir 22 days methylprednisolone 31 days | Decreased arousal, spastic quadriparesis, severe dysphagia, tracheostomy dependence (5) |
| Bilodeau et al. (9) | Male, 74 | Hypertension, Hyperlipidemia | No | Right peripheral facial palsy, mild bilateral abducens palsies, loss of consciousness event | 3 days | Ischemic lesions in right frontal | Left middle cerebral artery right middle cerebral artery | Elevation protein, cells 47 × 106/L (lymphocyte-predominant), VZV IgG (+) | IV and oral acyclovir 14 days, oral prednisone 14 days | Persistent right facial weakness (1) |
The characteristics of 9 varicella-zoster virus vasculopathy after Ramsay Hunt Syndrome cases.
The average time from symptom onset to MRI scan is 14 days. 88.9% (8/9) of the cases showed abnormal brain imaging results, including 8 cases of ischemic stroke, one of which also presented with microbleeds unrelated to the ischemic stroke. Among the ischemic stroke cases, 3 (37.5%, 3/8) had isolated lesions, 5 (63.5%, 5/8) had multifocal lesions. All 9 patients underwent vascular studies, revealing vascular abnormalities in 6 cases. The predominant findings were mixed arterial disease (5/9), small artery disease or large artery disease less commonly (2/9). Combined involvement of both anterior and posterior circulation was the most common pattern (66.7%, 6/9), followed by isolated anterior circulation involvement (22.2%, 2/9), with isolated posterior circulation being the least frequent (11.1%, 1/9). CSF analysis revealed pleocytosis in 66.7% (6/9) of patients. Among the cohort, 5 patients tested positive for VZV IgG antibodies, and 5 tested positive for VZV DNA by PCR; both markers were concurrently positive in 2 cases. All patients received acyclovir therapy, either as monotherapy (22.2%, 2/9) or in combination with corticosteroids (77.8%, 7/9). Only one patient received antiplatelet therapy. A favorable clinical outcome was observed in 88.9% (8/9) of patients (Table 2).
Table 2
| Demographics (n = 9) | ||
| Median age, years | 54.0 ± 16.5 | (24–75) |
| Male gender | 44.4% | 4/9 |
| History of varicella or zoster | 11.1% | 1/9 |
| Immunosuppression | 22.2% | 2/9 |
| Diabetes | 22.2% | 2/9 |
| Ramsay Hunt Syndrome | ||
| Vesicular rash | 55.6% | 5/9 |
| Deafness | 44.4% | 4/9 |
| Dizzy | 22.2% | 2/9 |
| Nystagmus | 22.2% | 2/9 |
| Other CNS clinical features | ||
| Encephalitis | 33.3% | 3/9 |
| Hemiplegia | 22.2% | 2/9 |
| Ataxia | 33.3% | 3/9 |
| Cranial nerve injury | 77.8% | 7/9 |
| Abnormal facial sensation (N = 3) | ||
| Dysarthria/dysphagia (N = 2) | ||
| Extraocular muscle paralysis (N = 5) | ||
| Diagnostic testing | ||
| PCR positive for VZV (CSF) | 55.6% | 5/9 |
| Anti-VZV IgG positive for VZV (CSF) | 55.6% | 5/9 |
| Both PCR and anti-VZV IgG positive for VZV (CSF) | 22.2% | 2/9 |
| Anti-VZV IgM positive for VZV (CSF) | 11.1% | 1/9 |
| CSF findings | ||
| Pleocytosis (> 4 cells/μl) | 66.7% | 6/9 |
| Elevation protein | 77.8% | 7/9 |
| Neuroimaging | ||
| Days from symptom onset to MRI (IQR) | 14.0 | (3–365) |
| Evidence for stroke | 88.9% | 8/9 |
| Ischemic stroke (N = 8) | ||
| Hemorrhagic stroke (N = 1) | ||
| Distribution of lesions (N = 8) | ||
| Single | 37.5% | 3/8 |
| Multiple | 62.5% | 5/8 |
| Affected areas of circulation | ||
| Anterior | 22.2% | 2/9 |
| Posterior | 11.1% | 1/9 |
| Mixed | 66.7% | 6/9 |
| Evidence for vasculitis by angiography | 66.7% | 6/9 |
| Small-sized vessels (N = 2) | ||
| Large-sized vessels (N = 2) | ||
| small and large vessel (N = 5) | ||
| Treatment | ||
| Acyclovir treatment alone | 22.2% | 2/9 |
| Acyclovir + steroid treatment | 77.8% | 7/9 |
| Anti-platelet medication | 11.1% | 1/9 |
| Outcome | ||
| Good outcome (mRS 0–2) | 88.9% | 8/9 |
| Unfavorable outcome (mRS 3–5) | 11.1% | 1/9 |
Demographics, clinical features, imaging abnormalities, and outcome.
Discussion
This literature review of nine cases of Ramsay Hunt Syndrome Type II (RHS II) complicated by varicella-zoster virus (VZV) vasculopathy provides critical insights into its clinical presentation, neuroimaging findings, diagnostic approaches, and therapeutic outcomes. The findings demonstrate that VZV vasculopathy can occur in both immunocompetent and immunocompromised patients, with a median age of 54 years. Cranial nerve dysfunction, particularly ophthalmoplegia, emerged as the predominant clinical feature (77.8%), while neuroimaging revealed abnormalities in 88.9% of cases, predominantly ischemic stroke (8/9 cases). Vascular abnormalities were identified in 66.7% of cases, and cerebrospinal fluid (CSF) analysis showed equivalent sensitivity for VZV IgG antibodies and VZV DNA (55.6% each). Treatment with acyclovir, frequently combined with corticosteroids (77.8%), yielded favorable outcomes in 88.9% of patients, underscoring the effectiveness of combined antiviral and corticosteroid therapy in managing this rare yet severe complication of RHS II.
Following primary chickenpox infection, VZV can remain dormant in the host’s ganglia for extended periods. When the immune status changes, VZV can reactivate, leading to central nervous system complications such as RHS II and VZV vasculopathy (2–4). Current research indicates that immunocompromised is a significant risk factor for VZV reactivation, and these patients are more susceptible to developing complications and have a more severe clinical picture (2). Therefore, we have reason to speculate that immunocompromise may be more pronounced when RHS II and VZV vasculopathy coexist. However, similar to previous studies (19), our results show that only 22.2% of the patients were immunosuppressed. This counterintuitive result may be related to genetic susceptibility factors. For instance, Sironi et al. (20) proposed that mutations in toll-like receptor 3 or its pathway might increase the risk of viral dissemination into the central nervous system. Another plausible explanation is the impairment of the immune system due to aging. In our review, the average age was 54.0 ± 16.5 years, consistent with findings from studies on RHS II with concurrent VZV encephalitis (19), which were notably higher than patients with RHS II alone (21). Additionally, Studies have found that diabetic patients are more susceptible to herpes zoster, with a risk 1.6 times higher than that of non-diabetic patients (22, 44). Furthermore, even in diabetic patients who have never had herpes zoster, VZV antigen can still be detected in the adventitia of cerebral arteries, along with vascular lesions (23). This indicates that diabetes is an important risk factor for VZV vasculopathy. In this study, 2 out of 7 immunocompetent patients had diabetes, further supporting the role of diabetes as a significant risk factor for both herpes zoster and VZV vasculopathy.
Although the appearance of vesicular rash helps in the diagnosis of RHS II, it is not a necessary condition. Current research has found that up to 30% of RHS II cases do not exhibit vesicular rash throughout the entire course (3), which is consistent with our findings. RHS II is characterized by herpetic inflammation of the geniculate ganglion of the facial nerve, sometimes accompanied by involvement of the vestibulocochlear nerve, leading to symptoms such as vertigo, nystagmus, tinnitus, hearing loss, hyperacusis, nausea, and vomiting (43). Additionally, the V, VI, IX, X, XI, and XII cranial nerves are occasionally affected, causing ophthalmoplegia, facial sensorimotor changes, bulbar dysfunction, and neck weakness (3, 24, 25). The mechanism by which RHS II leads to multiple intracranial neuropathies and vascular damage is not yet fully understood. Currently, several potential mechanisms have been proposed to explain how the virus spreads to intracranial blood vessels and nerves. Firstly, anatomical proximity may facilitate the spread of the virus between adjacent nerves both inside and outside the cranium, such as the anastomotic connection between the auricular branch of the vagus nerve and the facial nerve in the external auditory canal, as well as the anastomotic connection between the glossopharyngeal nerve and the tympanic membrane. Additionally, the facial nerve passes through the dura mater on its way out from the brainstem nucleus, which could allow for direct viral spread between the nerves and the meninges (24, 26). Secondly, CSF and the external lymphatic fluid of the inner ear are thought to play a role in the transmission of the virus between the facial nerve and cochlear nerve (27). Furthermore, the blood supply between the internal carotid artery, meningeal arteries, and pharyngeal ascending artery may enable the virus to spread hematogenously between multiple cranial nerves (28, 29). Lastly, dysregulated immune modulation proteins and chemokines resulting from abnormal activation of the post-infection defense mechanisms are also thought to be involved in the pathogenesis of VZV-induced neurological diseases (30). In our review, we found that, apart from RHS II-related symptoms, extraocular muscle paralysis was the most prominent symptom. This is inconsistent with previous findings that the glossopharyngeal and vagus nerves are most commonly affected in RHS II patients with intracranial nerves damage (31, 32). This further highlights how the combination of different mechanisms leads to the diversity of clinical symptoms. In addition, we found that 33.3% of patients experienced ataxia. Previous studies have shown that the occurrence of ataxia in RHS II often indicates the presence of acute cerebellitis (33, 34). These findings suggest that when patients with RHS II present with symptoms such as extraocular muscle paralysis or ataxia, careful consideration should be given to identifying potential intracranial complications, particularly VZV vasculopathy. In the past few decades, there has been a deep understanding of the clinical spectrum of VZV vasculopathy, which is prominently characterized by multiple ischemic strokes involving both the anterior and posterior circulations. Vascular examinations revealed that the involvement of both large and small arteries was more common than that of either alone (8). This is consistent with the findings of our review.
Confirmatory laboratory diagnosis of VZV vasculopathy is made by the presence of VZV DNA or anti-VZV antibody in the CSF. However, as time progresses and the disease advances, IgM and VZV DNA levels decrease, making VZV IgG detection the sole diagnostic strategy (8, 35). As suggested in previous reports, our review also emphasizes that the detection of VZV IgG antibodies in CSF has higher sensitivity for diagnosing VZV vasculopathy in patients with RHS II. However, the similar positivity rates of VZV IgG and VZV DNA further emphasize the short interval from RHS II to VZV vasculopathy. Consistent with our review results, routine CSF examinations for VZV vasculopathy are not specific and often indicate mononuclear pleocytosis, increased protein levels, and normal glucose levels (8). In recent years, some researchers have found that CSF levels of IL-8, IL-6, and MMP-2 are significantly elevated in patients with VZV vasculopathy (36). Since IL-8 is a chemotactic factor for neutrophils and IL-6 promotes macrophage differentiation, these findings may help explain the abundance of neutrophils and macrophages observed in patients with VZV vasculopathy.
Antiviral treatment has been widely accepted as the first-line therapeutic approach for VZV infections, although the optimal choice of drug, dose, and duration of treatment are not firmly established (8). Currently, the main focus of discussions regarding the treatment of VZV central nervous system infections centers on whether antiviral therapy should be combined with corticosteroids. Some studies suggest that combination therapy results in better prognosis for patients (3, 8), which is consistent with our findings. However, Wu et al. (37) study suggests that there is no significant difference in mortality or good prognosis between using antiviral drugs alone and combining antiviral drugs with corticosteroids, indicating that the role of glucocorticoids in the treatment of VZV vasculopathy remains unclear. Current research on the treatment of VZV vasculopathy highlights a significant gap in the investigation of antiplatelet therapy. While studies on HIV-and tuberculosis-related vasculitis have demonstrated that aspirin can reduce the risk of stroke (38). In our review, one patient received antiplatelet therapy and showed a very good prognosis. However, this patient also received antiviral drugs and steroids. Therefore, the efficacy of antiplatelet drugs in VZV-related ischemic stroke still requires further clinical validation. Due to the lack of specific therapeutic drugs, vaccination, including the live attenuated zoster vaccine (ZVL) and the inactivated adjuvant recombinant zoster vaccine (RZV), has been proven to be one of the most cost-effective strategies for preventing VZV infection (39, 40).
Previous studies have shown that the prognosis of patients with VZV involving the nervous system is related to multiple factors, including the timing of medication initiation, treatment duration, and whether corticosteroids are used in combination. Among these, earlier antiviral treatment is key, the longer the delay in antiviral treatment, the worse the prognosis (41, 42). In this study, VZV vascular disease occurred after the clinical symptoms of RHS II, leading to relatively early application of antiviral drugs, often in combination with corticosteroid treatment, resulting in a generally good prognosis, which is consistent with previous research findings.
Conclusion
This review conducted an in-depth exploration of the coexistence of VZV vasculopathy and RHS II, revealing several key points. Firstly, VZV vasculopathy, as a rare complication in RHS II patients, has ophthalmoplegia as a prominent symptom. The detection of IgG and PCR DNA in CSF has proven to be effective diagnostic markers for the coexistence of VZV vasculopathy and RHS II. Second, the results indicate that despite the simultaneous occurrence of these two conditions, the combination of antiviral therapy and steroids has achieved favorable outcomes in nearly all patients. This finding not only validates the effectiveness of current treatment strategies but also provides directions for optimizing future therapeutic approaches. Although this review provides valuable insights, we must acknowledge its limitations. Specifically, the potential publication bias in reports of severe cerebrovascular diseases may affect the generalizability of the conclusions. Therefore, we call for larger-scale, evidence-based medical research in the future to draw more meaningful conclusions. In summary, the findings of this review provide important evidence for a deeper understanding of the coexistence of VZV vasculopathy and RHS II, but further research is needed to enhance the understanding of this field.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.
Author contributions
DW: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft. MS: Conceptualization, Formal analysis, Methodology, Project administration, Supervision, Validation, Visualization, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Gen AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
Steiner I Kennedy PGE Pachner AR . The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol. (2007) 6:1015–28. doi: 10.1016/S1474-4422(07)70267-3
2.
Gershon AA Breuer J Cohen JI Cohrs RJ Gershon MD Gilden D et al . Varicella zoster virus infection. Nat Rev Dis Primers. (2015) 1:15016. doi: 10.1038/nrdp.2015.16
3.
Goswami Y Gaurkar SS . Ramsay hunt syndrome: an introduction, signs and symptoms, and treatment. Cureus. (2023) 15:e33688. doi: 10.7759/cureus.33688
4.
Nagel MA Traktinskiy I Stenmark KR Frid MG Choe A Gilden D . Varicella-zoster virus vasculopathy: immune characteristics of virus-infected arteries. Neurology. (2013) 80:62–8. doi: 10.1212/WNL.0b013e31827b1ab9
5.
Gilbert GJ . Herpes zoster ophthalmicus and delayed contralateral hemiparesis. JAMA. (1974) 229:302–4. doi: 10.1001/jama.1974.03230410026018
6.
Sreenivasan N Basit S Wohlfahrt J Pasternak B Munch TN Nielsen LP . The short-and long-term risk of stroke after herpes zoster—a nationwide population-based cohort study. PLoS One. (2013) 8:1–5. doi: 10.1371/journal.pone.0069156
7.
Yawn BP Wollan PC Nagel MA Gilden D . Risk of stroke and myocardial infarction after herpes zoster in older adults in a US community population. Mayo Clin Proc. (2016) 91:33–44. doi: 10.1016/j.mayocp.2015.09.015
8.
Gilden D Cohrs RJ Mahalingam R Nagel MA . Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment. Lancet Neurol. (2009) 8:731–40. doi: 10.1016/S1474-4422(09)70134-6
9.
Bilodeau PA Aghajan Y Izzy S . Rash, facial droop, and multifocal intracranial stenosis due to varicella zoster virus vasculitis. Neurohospitalist. (2023) 13:178–82. doi: 10.1177/19418744221150301
10.
Calabria F Zappini F Vattemi G Tinazzi M . Pearls & oy-sters: an unusual case of varicella-zoster virus cerebellitis and vasculopathy. Neurology. (2014) 82:e14–5. doi: 10.1212/WNL.0000000000000011
11.
Chan TLH Cartagena AM Bombassaro AM Hosseini-Moghaddam SM . Ramsay hunt syndrome associated with central nervous system involvement in an adult. Can J Infect Dis Med Microbiol. (2016) 2016:9859816–4. doi: 10.1155/2016/9859816
12.
González-Otárula KA Bruno V Pujol-Lereis VA Ameriso SF . Cerebral varicella-zoster vasculopathy sine herpete: atypical Ramsay-hunt syndrome in an immunocompetent patient. Neurol Clin Pract. (2014) 4:260–2. doi: 10.1212/CPJ.0000000000000005
13.
Labbad I Saleh Y Hazzouri B Samra DA Maksoud R . Polyneuritis cranialis and vasculopathy caused by varicella zoster virus without rash. Acta Neurol Belg. (2020) 120:1029–32. doi: 10.1007/s13760-020-01395-2
14.
Ohtomo R Shirota Y Iwata A Shimizu J Tsuji S . Cerebral microbleeding in varicella-zoster viral meningitis: an early sign of vasculopathy?Neurology. (2014) 82:814–5. doi: 10.1212/WNL.0000000000000165
15.
Ortiz GA Koch S Forteza A Romano J . Ramsay hunt syndrome followed by multifocal vasculopathy and posterior circulation strokes. Neurology. (2008) 70:1049–51. doi: 10.1212/01.wnl.0000306634.51885.87
16.
Russman AN Lederman RJ Calabrese LH Embi PJ Forghani B Gilden DH . Multifocal varicella-zoster virus vasculopathy without rash. Arch Neurol. (2003) 60:1607–9. doi: 10.1001/archneur.60.11.1607
17.
Upreti G Rathod K . Zoster polyneuritis Cranialis and intracranial vasculopathy. Indian J Otolaryngol Head Neck Surg. (2023) 75:971–4. doi: 10.1007/s12070-022-03235-6. Epub 2022 Nov 5
18.
Garkowski A Zajkowska J Zajkowska A Kułakowska A Zajkowska O Kubas B et al . Cerebrovascular manifestations of Lyme Neuroborreliosis-a systematic review of published cases. Front Neurol. (2017) 8:146. doi: 10.3389/fneur.2017.00146
19.
Ricigliano VAG Saraceno L Cavalli M Rodegher M Meola G . Slowly progressing varicella zoster brainstem encephalitis complicating Ramsay hunt syndrome in an immunocompetent patient: case report and review of the literature. J Neurovirol. (2017) 23:922–8. doi: 10.1007/s13365-017-0575-3
20.
Sironi M Peri AM Cagliani R Forni D Riva S Biasin M et al . TLR3 mutations in adult patients with herpes simplex virus and varicella zoster virus encephalitis. J Infect Dis. (2017) 215:1430–4. doi: 10.1093/infdis/jix166
21.
Chung SH Kim JM Rim HS Yeo SG Kim SH . Association between serum varicella-zoster virus IgM and IgG and prognosis of Ramsay hunt syndrome. J Clin Med. (2023) 12:5164. doi: 10.3390/jcm12155164
22.
Lai SW Liu CS Kuo YH Lin CL Hwang BF Liao KF . The incidence of herpes zoster in patients with diabetes mellitus: a meta-analysis of cohort studies. Medicine (Baltimore). (2021) 100:e25292. doi: 10.1097/MD.0000000000025292
23.
Nagel MA Traktinskiy I Choe A Rempel A Gilden D . Varicella-zoster virus expression in the cerebral arteries of diabetic subjects. Arch Neurol. (2012) 69:142–4. doi: 10.1001/archneur.69.1.142
24.
Gunbey HP Kutlar G Aslan K Sayit AT Incesu L . Magnetic resonance imaging evidence of varicella zoster virus polyneuropathy: involvement of the glossopharyngeal and vagus nerves associated with ramsay hunt syndrome. J Craniofac Surg. (2016) 27:721–3. doi: 10.1097/SCS.0000000000002583
25.
Xanthopoulos J Noussios G Papaioannides D Exarchakos G Assimakopoulos D . Ramsay Hunt syndrome presenting as a cranial polyneuropathy. Acta Otorhinolaryngol Belg. (2022) 56:319–23.
26.
Ottaiano AC Gomez GD Freddi TAL . The facial nerve: anatomy and pathology. Semin Ultrasound CT MR. (2023) 44:71–80. doi: 10.1053/j.sult.2022.11.005
27.
Kim C Choi H Shin J . Characteristics of hearing loss in patients with herpes zoster oticus. Medicine (Baltimore). (2016) 95:e5438. doi: 10.1097/MD.0000000000005438
28.
Nishioka K Fujishima K Kobayashi H Mizuno Y Okuma Y . An extremely unusual presentation of varicella zoster viral infection of cranial nerves mimicking Garcin syndrome. Clin Neurol Neurosurg. (2006) 108:772–4. doi: 10.1016/j.clineuro.2005.09.002
29.
Van Den Bossche P Van Den Bossche K Vanpoucke H . Laryngeal zoster with multiple cranial nerve palsies. Eur Arch Otorrinolaringol. (2008) 265:365–7. doi: 10.1007/s00405-007-0434-6
30.
Liu H Wang J Zhang Y Gu J Wang Y Yan Y et al . Cerebrospinal fluid proteomics in meningitis patients with reactivated varicella zoster virus. Immun Inflamm Dis. (2023) 11:e1038. doi: 10.1002/iid3.1038
31.
Nisa L Landis BN Giger R Leuchter I . Pharyngolaryngeal involvement by varicella-zoster virus. J Voice. (2013) 27:636–41. doi: 10.1016/j.jvoice.2013.02.011
32.
Shim HJ Jung H Park DC Lee JH Yeo SG . Ramsay hunt syndrome with multicranial nerve involvement. Acta Otolaryngol. (2011) 131:210–5. doi: 10.3109/00016489.2010.520167
33.
Park HK Lee JH . A case of ramsay hunt syndrome complicated by cerebellitis. J Clin Neurol. (2006) 2:198–201. doi: 10.3988/jcn.2006.2.3.198
34.
Ratzka P Schlachetzki JC Bähr M Nau R . Varicella zoster virus cerebellitis in a 66-year-old patient without herpes zoster. Lancet. (2006) 367:182. doi: 10.1016/S0140-6736(06)67967-1
35.
Nagel MA Forghani B Mahalingam R Wellish MC Cohrs RJ Russman AN et al . The value of detecting anti-VZV IgG antibody in CSF to diagnose VZV vasculopathy. Neurology. (2007) 68:1069–73. doi: 10.1212/01.wnl.0000258549.13334.16. Epub 2007 Feb 7
36.
Jones D Alvarez E Selva S Gilden D Nagel MA . Proinflammatory cytokines and matrix metalloproteinases in CSF of patients with VZV vasculopathy. Neurol Neuroimmunol Neuroinflamm. (2016) 3:3246. doi: 10.1212/NXI.0000000000000246
37.
Wu H Wang R Li Y Sun X Li J Bi X . Cerebrovascular complications after adult-onset varicella-zoster virus encephalitis in the central nervous system: a literature review. Neuropsychiatr Dis Treat. (2022) 18:449–62. doi: 10.2147/NDT.S343846
38.
Carod Artal FJ . Clinical management of infectious cerebral vasculitides. Expert Rev Neurother. (2016) 16:205–21. doi: 10.1586/14737175.2015.1134321
39.
Curran D Oostvogels L Heineman T Matthews S McElhaney J McNeil S et al . Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50 years and older. J Gerontol A Biol Sci Med Sci. (2019) 74:1231–8. doi: 10.1093/gerona/gly150
40.
Gershon A Gershon M Shapiro ED . Live attenuated varicella vaccine: prevention of varicella and of zoster. J Infect Dis. (2021) 224:S387–97. doi: 10.1093/infdis/jiaa573
41.
Arruti M Piñeiro LD Salicio Y Cilla G Goenaga MA López De Munain A . Incidence of varicella zoster virus infections of the central nervous system in the elderly: a large tertiary hospital-based series (2007–2014). J Neurovirol. (2017) 23:451–9. doi: 10.1007/s13365-017-0519-y
42.
Yan Y Yuan Y Wang J Zhang Y Liu H Zhang Z . Meningitis/meningoencephalitis caused by varicella zoster virus reactivation: a retrospective single-center case series study. Am J Transl Res. (2022) 15:491–500.
43.
Iwasaki H Toda N Takahashi M Azuma T Nakamura K Takao S et al . Vestibular and cochlear neuritis in patients with Ramsay hunt syndrome: a Gd-enhanced MRI study. Acta Otolaryngol. (2013) 133:373–7. doi: 10.3109/00016489.2012.750735
44.
Syal R Tyagi I Goyal A . Bilateral Ramsay Hunt syndrome in a diabetic patient. BMC Ear Nose Throat Disord. (2004) 4:3. doi: 10.1186/1472-6815-4-3
Summary
Keywords
Ramsay Hunt Syndrome, herpes zoster oticus, varicella zoster virus, stroke, VZV vasculopathy
Citation
Wu D and Song M (2025) Varicella-zoster virus vasculopathy: a rare complication of Ramsay Hunt Syndrome: a literature review. Front. Neurol. 16:1509110. doi: 10.3389/fneur.2025.1509110
Received
10 October 2024
Accepted
04 June 2025
Published
19 June 2025
Volume
16 - 2025
Edited by
U. K. Misra, Apollo Medics Super Speciality Hospital, India
Reviewed by
Sanghamitra Laskar, Vardhman Mahavir Medical College & Safdarjung Hospital, India
Rajat Madan, University of Cincinnati, United States
Mukesh Kumar, T. S. Misra Medical College & Hospital, India
Updates
Copyright
© 2025 Wu and Song.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mian Song, songm12024@126.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.